891853-90-0

Upstream product

• 3344-77-2 12-bromododecanol 
• 891853-88-6 2-[benzenesulfonyl-(12-hydroxy-dodecyl)-amino]-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 911289-62-8 2-[benzenesulfonyl-(12-methanesulfonyloxy-dodecyl)-amino]-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 234080-72-9 t-butyl (2S)-benzenesulfonylamino-3-[4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzoylamino]-propionate 

Downstream Products

• 891853-86-4 2-{benzenesulfonyl-[12-(benzenesulfonyl-{1-tert-butoxycarbonyl-2-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-ethyl}-amino)-dodecyl]-amino}-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 891853-94-4 (S)-2-{Benzenesulfonyl-[12-(benzenesulfonyl-{(S)-1-carboxy-2-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-ethyl}-amino)-dodecyl]-amino}-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid 

Relevant academic research and scientific papers

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

To establish the in vivo efficacy of αvβ3/αIIbβ3 dual antagonists possessing a tricyclic pharmacophore, a corresponding αvβ3-selective antagonist was required as a control. We initially too